Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497418 | 0.84 | TSHR (0.48) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL21164831 | 0.82 | USP2 (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3595211 | 0.80 | USP2 (0.55) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10054624 | 0.79 | USP2 (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL369391 | 0.79 | TSHR (0.43) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL19257180 | 0.77 | KDM4E (0.41) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25896439 | 0.77 | KDM4E (0.41) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL22808901 | 0.77 | TSHR (0.46) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9111200 | 0.76 | USP2 (0.50) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL3369383 | 0.76 | ALDH1A1 (0.50) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494671-B1 | 1-(4-PIPERIDINYL)BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS | SCHERING CORP (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1494671-A1 | 1-(4-PIPERIDINYL)BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040048843-A1 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION | 2004-03-11 | — | — | US | disclosed |
| WO-2003103669-A1 | 1-(4-PIPERIDINYL) BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048843-A1 | Benzimidazolone histamine H3 antagonists | HRH2, HRH1, HRH4 | USP2 3508/4885TSHR 659/4885KDM4E 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.